De-escalating Antiplatelet Therapy to Assess Platelet Reactivity and Outcomes in High Bleeding Risk Patients With Recent ACS

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT05903976

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Azienda Ospedaliera Universitaria Policlinico "G. Martino" (from the registry)
Registry
  • NCT NCT05903976
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05903976. Randomized; no masking; primary purpose treatment. Start 2023-06-12 (actual); primary completion 2025-06-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
De-escalating Antiplatelet Therapy to Assess Platelet Reactivity and Outcomes in High Bleeding Risk Patients With Recent ACS
Acronym
DESC-HBR
Condition
Dual Antiplatelet Therapy
Condition
Acute Coronary Syndrome
Intervention (Drug)
P2Y12 inhibitor de-escalation
Lead sponsor
Azienda Ospedaliera Universitaria Policlinico "G. Martino" (class: other)
Collaborator
Giampiero Vizzari (class: not stated)
Collaborator
Giorgio Quadri (class: not stated)
Collaborator
Greca Zanda (class: not stated)
Collaborator
Ferdinando Varbella (class: not stated)
Collaborator
Gianluca Di Bella (class: not stated)
Collaborator
Antonio Micari (class: not stated)

Record details

Record id
cardio:ct-nct05903976
Content hash
dd7036a7d88633c6d6a7687f7f25db2983f954f28a22b056aa6af584c1b1c526